Catalyst
Slingshot members are tracking this event:
Tal Medical (PTCHF) Completes Phase 2 Dose Optimization Study of Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
- Source Link:
- https://clinicaltrials.gov/ct2/show/NCT02452892
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| Tal Medical |
|
|
PTCHF |
|
|
|
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 11, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Dose Optimization Study, Trial Completion, Low Field Magnetic Stimulation, Lfms, Treatment-resistant Depression, Trd, Solidd
